MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Начало・Списък с акции・Cogent Biosciences Inc

Cogent Biosciences Inc

Затворен

37.63 7.15

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

34.72

Максимум

38.34

Ключови измерители
By Trading Economics
Приходи	-7.4M -81M
EPS	-0.5
Служители	205
EBITDA	-6.8M -79M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+44.56% upside

Дивиденти
By Dow Jones
Следващи печалби	24.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	3.2B 5.3B
Предишно отваряне	30.48
Предишно затваряне	37.63

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

4.88 / 5.87 Подкрепа & съпротива

Cogent Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.01.2026 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15.01.2026 г., 00:00 ч. UTC

Печалби

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14.01.2026 г., 23:47 ч. UTC

Пазарно говорене

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14.01.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14.01.2026 г., 23:39 ч. UTC

Пазарно говорене

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14.01.2026 г., 23:32 ч. UTC

Пазарно говорене

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14.01.2026 г., 22:56 ч. UTC

Придобивния, сливания и поглъщания

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14.01.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14.01.2026 г., 22:17 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

14.01.2026 г., 22:17 ч. UTC

Пазарно говорене

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14.01.2026 г., 22:09 ч. UTC

Печалби

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14.01.2026 г., 22:08 ч. UTC

Печалби

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14.01.2026 г., 22:08 ч. UTC

Печалби

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14.01.2026 г., 21:53 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14.01.2026 г., 21:53 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14.01.2026 г., 21:52 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Announces Positive Profit Alert for 2025

14.01.2026 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

Citigroup Acting as Financial Advisor to WuXi XDC

14.01.2026 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC: Aims to Keep Listing Status of BioDlink

14.01.2026 г., 21:51 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Financial Services Roundup: Market Talk

14.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

14.01.2026 г., 21:49 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14.01.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14.01.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

WuXi XDC Makes Cash Offer for BioDlink International

14.01.2026 г., 21:13 ч. UTC

Пазарно говорене

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14.01.2026 г., 20:30 ч. UTC

Пазарно говорене

Печалби

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14.01.2026 г., 20:13 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14.01.2026 г., 20:08 ч. UTC

Пазарно говорене

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14.01.2026 г., 19:33 ч. UTC

Пазарно говорене

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14.01.2026 г., 19:06 ч. UTC

Пазарно говорене

Печалби

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Cogent Biosciences Inc Прогноза

Ценова цел

By TipRanks

44.56% нагоре

12-месечна прогноза

Среден 50.25 USD 44.56%

Висок 67 USD

Нисък 34 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Cogent Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Cogent Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

4.88 / 5.87Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.